Seaport Therapeutics Inc. (SPTX) Options Positioning, Max Pain & Unusual Sweeps

SPTX scores 55 out of 100, equivalent to a letter grade of D+ and the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars break down as follows:

• Fundamental Cash Engine: 10 / 20. The pillar reflects ROIC of 0% and FCF yield of 0%, indicating no measurable return on capital or free cash generation in the source data.
• Whale 13F Flow: 10 / 20. This pillar covers institutional accumulation and options positioning; the source assigns a mid-to-low score without further detail on specific holders.
• Insider Conviction: 9 / 20. This is the lowest pillar, covering SEC Form 4 and Congressional PTR cluster flow, indicating weak insider signaling in the source data.
• Macro Regime Fit: 13 / 20. Beta is 1.0, and the sector sensitivity assessment is moderate.
• Forensic Balance Sheet: 13 / 20. Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5 form the basis of this score.

For a prospective investor evaluating the stock today, the rating points to a company whose current operating profile does not yet generate returns or cash flow, with the balance sheet and macro sensitivity being the relatively stronger components. Upside drivers would need to come from outside the cash engine, such as pipeline or trial developments referenced in the news wire, rather than from reported earnings. Valuation tradeoffs are significant: with the P/E, EV/EBITDA, and EPS metrics unavailable in the source data, the market price of $21.10 cannot be benchmarked against earnings. The 0% margin, ROIC, and FCF yield readings mean that the price relies on expectations not captured in the reported figures. This analysis is educational and does not constitute personalized financial advice.

Seaport Therapeutics Inc. (SPTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. —

FY 2025 reports — in revenue, operating income, and net income, with cash of $46.0M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. The reported profitability profile is absent in the source data, while the balance sheet metrics provide the only quantified stability indicators.

• 🐂 Primary Bull Case: The stock trades near $21.10 with a balance sheet pillar scoring 13 / 20, supported by an Altman Z of 2.5 and Piotroski F of 6/9. With Fundamental Cash Engine at 10/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 7/20, sustained execution supports upside toward the top of the $14.85 – $28.38 52-week range.
• 🐻 Primary Bear Case: With ROIC at 0%, FCF yield at 0%, and insider conviction scoring 9 / 20, the reported data shows no cash generation or insider signaling. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and beta of 1.0. Investors should watch the lock-up expiry of 28-OCT-2026 as the nearest identifiable supply-of-shares event, since it may affect trading dynamics in the stock.

• Key Question #1: What are the company's specific products, clinical pipeline stages, and revenue model, given that FY 2025 revenue is reported at —?
• Key Question #2: What is the cash runway implied by $46.0M of cash against the current operating loss profile, and how does the lock-up expiry interact with that runway?
• Key Question #3: What are the terms and scope of the trial referenced in the H.C. Wainwright headline?